EN 3001
Alternative Names: EN-3001Latest Information Update: 27 Nov 2020
At a glance
- Originator Enosi Life Sciences
- Class Antineoplastics
- Mechanism of Action Type II tumour necrosis factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer